

Help your patients get started with Aimovig® (erenumab-aooe) today

To assist patients throughout treatment, we've created a patient quick start guide outlining available support.

Provide the Patient Quick Start Guide for Aimovig® to your patients



Consider discussing the following to help your patients start and stay on Aimovig®:



Eligible commercially insured patients pay as little as **\$5 per month** with the Aimovig® Copay Card.* Note that patients with Medicare, Medicaid, or no insurance can call 833-AIMOVIG (833-246-6844).

*Eligibility criteria and program maximums apply. Terms and conditions apply. Please see full Terms and Conditions at aimovigcopaycard.com/tcs.



Patients asking for supplemental injection support can watch the **How to Take Aimovig® video**.



Patients can enroll in **AimAlly™ Support programs** to track monthly migraine days and receive refill reminders.



The American Headache Society recommends waiting **at least 3 months** before assessing the benefits of anti-CGRP preventative treatments like Aimovig®.¹

The Patient Quick Start Guide can help Aimovig® patients understand and access support throughout treatment

CGRP=calcitonin gene-related peptide.

INDICATION

Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Please see additional Important Safety Information on the next page.



IMPORTANT SAFETY INFORMATION (cont'd)

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies ($\geq 3\%$ of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please [click here](#) for Aimovig® full Prescribing Information.

Reference: 1. Ailani J, Burch RC, Robbins SR. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. *Headache*. 2021;61:1021-1039.

AMGEN®

© 2023 Amgen Inc. All rights reserved. USA-334-85748

 **aimovig**[®]
(erenumab-aooe) injection
70 mg/mL • 140 mg/mL